The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.

Published Date: 03 Jan 2024

The use of novel hormonal therapy (NHT) agents for Medicare beneficiaries with advanced prostate cancer (PCa) differs based on race, per a study published online Dec. 1 in JAMA Network Accessible.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

2.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

3.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

4.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

5.

The FDA Approves the New Frontline Aggressive ALL Regimen.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot